AI models need more data about biology, and OpenAI is paying to create it
TL;DR
Last year Ruxandra Teslo, a policy analyst who focuses on clinical trials, posted an idea for supercharging medical AI systems: Use data from failed biotech companies. By bidding at their bankruptcy proceedings, she proposed, it might be possible to obtain detailed regulatory filings, manufacturing strategies, and safety data—types of information usually considered trade secrets. She….
Nauti's Take
For small teams, the immediate lesson is to audit the data before testing the model: medical AI depends on regulatory, manufacturing, and safety records that are difficult to access publicly. Verify provenance, usage rights, freshness, and bias first, because data acquired through bankruptcy proceedings is not automatically reliable or free to use.
Summary
Last year Ruxandra Teslo, a policy analyst who focuses on clinical trials, posted an idea for supercharging medical AI systems: Use data from failed biotech companies. By bidding at their bankruptcy proceedings, she proposed, it might be possible to obtain detailed regulatory filings, manufacturing strategies, and safety data—types of information usually considered trade secrets.
She…
Sources